Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Spike-specific antibodies are central to effective COVID19 immunity. Research efforts have focused on antibodies that neutralize the ACE2-Spike interaction but not on non-neutralizing antibodies. Antibody-dependent phagocytosis is an immune mechanism enhanced by opsonization, where typically, more bound antibodies trigger a stronger phagocyte response. Here, we show that Spike-specific antibodies, dependent on concentration, can either enhance or reduce Spike-bead phagocytosis by monocytes independently of the antibody neutralization potential. Surprisingly, we find that both convalescent patient plasma and patient-derived monoclonal antibodies lead to maximum opsonization already at low levels of bound antibodies and is reduced as antibody binding to Spike protein increases. Moreover, we show that this Spike-dependent modulation of opsonization correlate with the outcome in an experimental SARS-CoV-2 infection model. These results suggest that the levels of anti-Spike antibodies could influence monocyte-mediated immune functions and propose that non-neutralizing antibodies could confer protection to SARS-CoV-2 infection by mediating phagocytosis.
Article activity feed
-
-
SciScore for 10.1101/2021.10.14.464464: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: All participants gave written informed consent to participate in the study which was approved by the Swedish ethical review authority (2020/01747).
IRB: All the animal experiments were performed under the approval of the regional animal experimental ethics committee in Stockholm (16765-2020).Sex as a biological variable Animal experiments: Forty-two nine-week old female K18 hACE2 (B6.Cg-Tg(K18-ACE2)2Prlmn/J) mice were inoculated intranasally with 105 PFU of SARS-CoV-2 (Wuhan strain, isolate SARS-CoV-2/01/human/2020/SWE, sourced from the Swedish Health Authorities). Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: …
SciScore for 10.1101/2021.10.14.464464: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: All participants gave written informed consent to participate in the study which was approved by the Swedish ethical review authority (2020/01747).
IRB: All the animal experiments were performed under the approval of the regional animal experimental ethics committee in Stockholm (16765-2020).Sex as a biological variable Animal experiments: Forty-two nine-week old female K18 hACE2 (B6.Cg-Tg(K18-ACE2)2Prlmn/J) mice were inoculated intranasally with 105 PFU of SARS-CoV-2 (Wuhan strain, isolate SARS-CoV-2/01/human/2020/SWE, sourced from the Swedish Health Authorities). Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The cells were then washed with PBS, blocked in 2% BSA and stained with antibodies against CD19-PE (BD-555413), CD3-BV510 (BD-564713), IgG-BV421 (BD-562581) and a live/Dead Sytox stain. CD19-PEsuggested: NoneCD3-BV510suggested: NoneBD-564713) , IgG-BV421suggested: NoneBD-562581suggested: NoneAfter 1 hour incubation at room temperature the wells were washed and bound scFv was detected by incubation for 40 minutes at room temperature with peroxidase labelled monoclonal anti-FLAG® M2 antibody (Sigma Aldrich (30 µl diluted 1/4000 in assay buffer) and development using 1-Step™ Ultra TMB-ELISA Substrate Solution (Thermo Fisher Scientific) anti-FLAG®suggested: NoneExperimental Models: Cell Lines Sentences Resources HEK293 cells constitutively expressing the ACE2 receptor were acquired from BEI resources (NR-52511). HEK293suggested: NoneTHP-1 cells were washed twice with PBS and reconstituted in Sodium medium. THP-1suggested: CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006)Pseudotyped lentiviruses displaying the SARS-CoV-2 pandemic founder variant (Wu-Hu-1) packaging a firefly luciferase reporter gene were generated by the co-transfection of HEK293T cells using Lipofectamine 3000 (Invitrogen) per the manufacturer’s protocols. HEK293Tsuggested: NoneFor these experiments, the HEK293T-hACE2 cell culture was supplemented with penicillin/streptomycin antibiotics to avoid contamination. HEK293T-hACE2suggested: RRID:CVCL_A7UK)Bead-based neutralization assay: HEK293T-ACE2 cells were seeded at density of 35,000 cells per well in a Poly-D-Lysine coated flat bottom 96 well plate. HEK293T-ACE2suggested: NoneExperimental Models: Organisms/Strains Sentences Resources Animal experiments: Forty-two nine-week old female K18 hACE2 (B6.Cg-Tg(K18-ACE2)2Prlmn/J) mice were inoculated intranasally with 105 PFU of SARS-CoV-2 (Wuhan strain, isolate SARS-CoV-2/01/human/2020/SWE, sourced from the Swedish Health Authorities). B6.Cg-Tg(K18-ACE2)2Prlmn/Jsuggested: RRID:IMSR_JAX:034860)Software and Algorithms Sentences Resources Once received, we collated the V(D)J regions from our antibodies of interest using the V-Loupe software (10X Genomics software platform). Genomicssuggested: (UTHSCSA Genomics Core, RRID:SCR_012239)Multiple sequence alignment using the ClustalW algorithm was performed on the light chain sequences and the heavy chain sequences. ClustalWsuggested: (ClustalW, RRID:SCR_017277)Apparent reaction rate kinetics was determined using a Langmuir 1:1 model using the Sierra Analyser software version 3.4.3 (Bruker). Sierra Analysersuggested: (OMICtools, RRID:SCR_002250)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 4. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
